Piper Sandler Cuts Price Target on Constellation Brands (STZ) as it Faces Headwinds From GLP-1 Weight Loss Drugs
Constellation Brands, Inc. (NYSE:STZ) ranks among the best sin stocks to buy in 2026. On November 21, Piper Sandler cut its price target for Constellation Brands, Inc. (NYSE:STZ) to $135 from $155 while keeping a Neutral rating for the alcohol company. The firm cited increasing strain from GLP-1 weight loss pharmaceuticals as a major reason […]
In 2025, the Marks and Spencer share price has turned £5,000 into…
2025 hasnât been a stellar 12 months for the Marks and Spencer (LSE: MKS) share price. The stock has fallen from 376p to 316p, turning a £5,000 investment at the start of the year into around £4,200 (note that investors would have also received/been entitled to 3.8p per share in dividends). So, what has gone […]
Biocon launches GLP-1 peptide, Liraglutide in the Netherlands
Under brand names Diavorin and Vobexoryn
Biocon launches its diabetes & obesity treatment drugs in Netherlands
Biocon has announced the launch of of its GLP-1 peptide, Liraglutide, for diabetes (gVictoza) and obesity (gSaxenda), in the Netherlands through its distribution partner Pharmamedic B.V.
WHO endorsement sparks new discussion around GLP-1 drugs and PCOS
The World Health Organization’s recent endorsement of GLP-1 medications, such as Ozempic, is prompting renewed discussion about their potential role in treating polycystic ovary syndrome (PCOS), a hormonal condition affecting millions. Canadian experts say the drugs may help address the metabolic dysfunction linked to PCOS, though more research is needed before they become standard care. […]
The New Diet Drugs vs. Exercise: Which Works Better?
The implications from the design of the clinical GLP-1 agonist trials and studies of caloric restriction are that exercise is basically irrelevant.
2 Predictions for Novo Nordisk in 2026
Key Points Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company’s pipeline candidates will see strong progress in 2026. Novo Nordisk’s shares appear attractive, despite the challenges it faces. 10 stocks we like better than Novo Nordisk › The past 18 months have […]
Chonky Kitties Beware: Ozempic for Cats Is on the Way
If your cat has reached a size best described as “majestically chonky,” science may soon have a solution that spares you from micromanaging every scoop. A weight-loss drug for cats, modeled after human medications like Ozempic, is now being tested in veterinary clinical trials. More than half of pet cats worldwide are estimated to be […]
Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy—a phase 2 randomized trial
Nature Communications, Published online: 14 December 2025; doi:10.1038/s41467-025-66167-z Semaglutide, a GLP-1 receptor agonist, may offer neuroprotective benefits after stroke, but its effects in large vessel occlusion (LVO) are unknown. Here the authors show, in a phase 2 randomized trial, that semaglutide is safe after endovascular therapy and may improve recovery in patients not receiving intravenous […]
COMMENTARY: The real story behind Trump’s GLP-1 price cut: Markets still rule
Price controls sap resources and ingenuity from America’s pharmaceutical sector